This project’s goal is to inform the policy debate on drug pricing in the remainder of 2019 by analyzing three Congressional or administration drug proposals as they are released. Each analysis will summarize the key provisions of a given proposal, discuss the pros and cons of each provision, weigh the value of the overall proposal, and suggest detailed improvements that can be made as the legislative or rulemaking process continues. The specific proposals analyzed may include: 1) revisions to the Senate Finance Committee proposal, which includes Part D benefit redesign, limits on spread pricing, inflation caps on Part B and D drug prices, and a series of reforms aimed at addressing smaller frictions to lower drug prices; 2) Medicare drug price negotiation proposals from House Democrats; 3) most-favored nation drug pricing proposals that have been suggested by the Trump administration.